Cladribine use for multiple sclerosis with autoimmune comorbidities: retrospective analysis of the French MS registry, case series, and therapeutic considerations
Vito A. G. Ricigliano(Inserm), de Sèze(Hôpital d'Hautepierre), Inès Masmoudi(Centre Hospitalier Universitaire Amiens-Picardie), Marine Boudot de la Motte(Fondation Ophtalmologique Adolphe de Rothschild), Eric Manchon(Centre Hospitalier de Gonesse)
Cited by 0
Related Papers
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
|Neurology|2015|4.6k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
|Journal of Neuroinflammation|2018|740
Ofatumumab versus Teriflunomide in Multiple Sclerosis
|New England Journal of Medicine|2020|706
Neuromyelitis Optica and Non–Organ-Specific Autoimmunity
|Archives of Neurology|2008|612